Reading Time: 7 minutes Global biotechnology company Biogen has announced plans to make tofersen, a potential treatment for people whose MND is believed to be driven by mutations in the SOD1 gene, available to more people on an early access programme. Biogen have also revealed that they are conducting a new Phase 3 clinical trial of tofersen in those…
Reading Time: 4 minutes While the exact cause of MND remains unknown, two of the hallmarks of the disease are a build-up, or aggregation, of toxic proteins in motor neurons and the misfolding of proteins. Protein folding is the physical process by which a protein chain becomes biologically functional. If it doesn’t fold properly, it can’t function properly. These…
Reading Time: 2 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials. Presented by Dr Merit Cudkowicz, from Harvard Medical School and Massachusetts General Hospital,…
